Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation

Dow Jones

Dec 25, 2024

By Josh Beckerman

Neuphoria Therapeutics shares closed up in their first Nasdaq trading day after Bionomics re-domiciled to the U.S. from Australia and Neuphoria became the ultimate parent company of Bionomics.

The stock finished 118% higher, at $6.63, and briefly paused for volatility at least 13 times during the shortened Tuesday trading session.

The biotechnology company focused on neuropsychiatric disorders said Oct. 1 that a re-domiciliation would eliminate significant Australian compliance costs, increase alignment with prominent U.S. pharmaceutical companies and improve marketability with U.S. institutional investors.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

December 24, 2024 13:49 ET (18:49 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2494030262"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494030262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494030262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-25 02:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494030262","market":"nz","top_or_hot":-1,"title":"Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Neuphoria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares closed up in their first Nasdaq trading day after <a href=\"https://laohu8.com/S/BNO.AU\">Bionomics</a> re-domiciled to the U.S. from Australia and Neuphoria became the ultimate parent company of Bionomics. \n</p>\n<p>\n  The stock finished 118% higher, at $6.63, and briefly paused for volatility at least 13 times during the shortened Tuesday trading session. \n</p>\n<p>\n  The biotechnology company focused on neuropsychiatric disorders said Oct. 1 that a re-domiciliation would eliminate significant Australian compliance costs, increase alignment with prominent U.S. pharmaceutical companies and improve marketability with U.S. institutional investors. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2024 13:49 ET (18:49 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-25 02:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Neuphoria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares closed up in their first Nasdaq trading day after <a href=\"https://laohu8.com/S/BNO.AU\">Bionomics</a> re-domiciled to the U.S. from Australia and Neuphoria became the ultimate parent company of Bionomics. \n</p>\n<p>\n  The stock finished 118% higher, at $6.63, and briefly paused for volatility at least 13 times during the shortened Tuesday trading session. \n</p>\n<p>\n  The biotechnology company focused on neuropsychiatric disorders said Oct. 1 that a re-domiciliation would eliminate significant Australian compliance costs, increase alignment with prominent U.S. pharmaceutical companies and improve marketability with U.S. institutional investors. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2024 13:49 ET (18:49 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494030262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494030262","pubTimestamp":1735066140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neuphoria Therapeutics shares closed up in their first Nasdaq trading day after Bionomics re-domiciled to the U.S. from Australia and Neuphoria became the ultimate parent company of Bionomics.The stock finished 118% higher, at $6.63, and briefly paused for volatility at least 13 times during the shortened Tuesday trading session.The biotechnology company focused on neuropsychiatric disorders said Oct. 1 that a re-domiciliation would eliminate significant Australian compliance costs, increase alignment with prominent U.S. pharmaceutical companies and improve marketability with U.S. institutional investors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","NEUP":"Neuphoria Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Bionomics重新注册后Neuphoria Therapeutics数量增加了一倍多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEUP":0.9,"LENZ":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Neuphoria Therapeutics shares closed up in their first Nasdaq trading day after Bionomics re-domiciled to the U.S. from Australia and Neuphoria became the ultimate parent company of Bionomics. \n\n\n  The stock finished 118% higher, at $6.63, and briefly paused for volatility at least 13 times during the shortened Tuesday trading session. \n\n\n  The biotechnology company focused on neuropsychiatric disorders said Oct. 1 that a re-domiciliation would eliminate significant Australian compliance costs, increase alignment with prominent U.S. pharmaceutical companies and improve marketability with U.S. institutional investors. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 24, 2024 13:49 ET (18:49 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}